Burkitt lymphoma and atypical burkitt or burkitt-like lymphoma: Should these be treated as different diseases?

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 58-66

  Thomas, Deborah A ^a   O'Brien, Susan ^a   Faderl, Stefan ^a   Manning Jr , John T ^a   Romaguera, Jorge ^a   Fayad, Luis ^a   Hagemeister, Fredrick ^a   Medeiros, Jeffrey ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Atypical Burkitt; Burkitt; Burkitt like; c myc; DLBCL; Non Hodgkin lymphoma; Therapy; WHO classification

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYC PROTEIN; PREDNISONE; RITUXIMAB; TUMOR MARKER; VINCRISTINE;

ARTICLE; ATYPICAL BURKITT LYMPHOMA; BURKITT LYMPHOMA; CANCER THERAPY; CONTINUOUS INFUSION; DISEASE MARKER; DISEASE SEVERITY; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENES, MYC; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING;

EID: 79551473158     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0076-4     Document Type: Article

References (48)

1. Diebold JE, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman J, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:181-184
2. JES The 2008 WHO classification of lymphomas: implications for clinical practice and translational research Hematology Am Soc Hematol Educ Program. 2009 523 531
3. DP Burkitt 1983 The discovery of Burkitt's lymphoma Cancer. 51 1777 1786 1:STN:280:DyaL3s7lsFSnsQ%3D%3D 10.1002/1097-0142(19830515)51:10<1777::AID- CNCR2820511003>3.0.CO;2-E 6299496
4. KA Blum G Lozanski JC Byrd 2004 Adult Burkitt leukemia and lymphoma Blood. 104 3009 3020 1:CAS:528:DC%2BD2cXhtVWhur%2FM 10.1182/blood-2004-02-0405 15265787 (Pubitemid 39507113)
5. JL Kutok F Wang 2006 Spectrum of Epstein-Barr virus-associated diseases Annu Rev Pathol. 1 375 404 1:CAS:528:DC%2BD28XktVOiurw%3D 10.1146/annurev. pathol.1.110304.100209 18039120
6. JL Hecht JC Aster 2000 Molecular biology of Burkitt's lymphoma J Clin Oncol. 18 3707 3721 1:CAS:528:DC%2BD3cXot1ant7w%3D 11054444
7. T Burmeister S Schwartz HA Horst, et al. 2005 Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features Leukemia. 19 1391 1398 1:CAS:528:DC%2BD2MXmtlSjsLk%3D 10.1038/sj.leu.2403847 15973450 (Pubitemid 41136333)
8. A Neri F Barriga DM Knowles IT Magrath R Dalla-Favera 1988 Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma Proc Natl Acad Sci U S A. 85 2748 2752 1:CAS:528:DyaL1cXitFOitLw%3D 10.1073/pnas.85.8.2748 2833750
9. K Klapproth T Wirth 2010 Advances in the understanding of MYC-induced lymphomagenesis Br J Haematol. 149 484 497 1:CAS:528:DC%2BC3cXns1eqt74%3D 10.1111/j.1365-2141.2010.08159.x 20346013
10. GM Mead SL Barrans W Qian, et al. 2008 A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial) Blood. 112 2248 2260 1:CAS:528:DC%2BD1cXhtFCrurjJ 10.1182/blood-2008-03-145128 18612102
11. RF McClure ED Remstein WR Macon, et al. 2005 Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior Am J Surg Pathol. 29 1652 1660 10.1097/01.pas. 0000180442.87022.08 16327438
12. H Mossafa D Damotte A Jenabian, et al. 2006 Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis Leuk Lymphoma. 47 1885 1893 1:CAS:528:DC%2BD28XhtlarurzI 10.1080/ 10428190600687547 17065002 (Pubitemid 44649774)
13. WY Au DE Horsman RD Gascoyne DS Viswanatha RJ Klasa JM Connors 2004 The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases Leuk Lymphoma. 45 519 528 1:CAS:528:DC%2BD3sXps1ansro%3D 10.1080/10428190310001593120 15160914 (Pubitemid 38196035)
14. S Barrans S Crouch A Smith, et al. 2010 Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab J Clin Oncol. 28 3360 3365 1:CAS:528: DC%2BC3cXhtVajurvL 10.1200/JCO.2009.26.3947 20498406
15. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
16. NL Harris ES Jaffe H Stein, et al. 1994 A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood. 84 1361 1392 1:STN:280:DyaK2czkvVSmtQ%3D%3D 8068936 (Pubitemid 24273002)
17. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
18. RM Braziel DA Arber ML Slovak, et al. 2001 The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features Blood. 97 3713 3720 1:CAS:528:DC%2BD3MXksVOqs74%3D 10.1182/blood.V97. 12.3713 11389007
19. E Haralambieva EJ Boerma GW van Imhoff, et al. 2005 Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma Am J Surg Pathol. 29 1086 1094 16006805
20. AS LaCasce ME Kho JW Friedberg, et al. 2008 Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network J Clin Oncol. 26 5107 5112 10.1200/JCO.2008.16.4061 18768434
21. RP Gormley R Madan AE Dulau, et al. 2005 Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases Am J Clin Pathol. 124 790 798 10.1309/7CEAWV0DNLLUWQTF 16203284
22. SS Dave K Fu GW Wright, et al. 2006 Molecular diagnosis of Burkitt's lymphoma N Engl J Med. 354 2431 2442 1:CAS:528:DC%2BD28XlsVaisro%3D 10.1056/NEJMoa055759 16760443 (Pubitemid 43855046)
23. M Hummel S Bentink H Berger, et al. 2006 A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling N Engl J Med. 354 2419 2430 1:CAS:528:DC%2BD28XlsVajur0%3D 10.1056/NEJMoa055351 16760442 (Pubitemid 43855045)
24. W Klapper M Szczepanowski B Burkhardt, et al. 2008 Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials Blood. 112 1374 1381 1:CAS:528:DC%2BD1cXpvVOktLY%3D 10.1182/blood-2008-01-136465 18509088
25. I Magrath M Adde A Shad, et al. 1996 Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen J Clin Oncol. 14 925 934 1:CAS:528:DyaK28Xit1GjsLk%3D 8622041
26. D Hoelzer WD Ludwig E Thiel, et al. 1996 Improved outcome in adult B-cell acute lymphoblastic leukemia Blood. 87 495 508 1:CAS:528:DyaK28XkvFSrsA%3D%3D 8555471
27. DA Thomas J Cortes S O'Brien, et al. 1999 Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia J Clin Oncol. 17 2461 2470 1:CAS:528:DyaK1MXltlyltL4%3D 10561310
28. EJ Lee GR Petroni CA Schiffer, et al. 2001 Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251 J Clin Oncol. 19 4014 4022 1:CAS:528:DC%2BD3MXotVCgtL8%3D 11600602
29. GM Mead MR Sydes J Walewski, et al. 2002 An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study Ann Oncol. 13 1264 1274 1:STN:280:DC%2BD38visVeqtQ%3D%3D 10.1093/annonc/mdf253 12181251 (Pubitemid 34960136)
30. DA Rizzieri JL Johnson D Niedzwiecki, et al. 2004 Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251 Cancer. 100 1438 1448 1:CAS:528:DC%2BD2cXjt1Sru78%3D 10.1002/cncr.20143 15042678 (Pubitemid 38366847)
31. A Lacasce O Howard S Lib, et al. 2004 Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity Leuk Lymphoma. 45 761 767 1:CAS:528:DC%2BD3sXpvV2lsbc%3D 10.1080/1042819031000141301 15160953 (Pubitemid 38256039)
32. DA Thomas S Faderl S O'Brien, et al. 2006 Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia Cancer. 106 1569 1580 1:CAS:528:DC%2BD28XjsFeru78%3D 10.1002/cncr.21776 16502413
33. K Dunleavy BR Healey Bird S Pittaluga, et al. 2007 Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma [abstract 8035] J Clin Oncol 25 449s 10.1200/JCO.2006.09.2346 (Pubitemid 350002996)
34. D Hoelzer W Hiddemann A Baumann, et al. 2007 High survival rate in adult Burkitt's lymphoma/leukemia and diffuse large B-cell lymphoma with mediastinal involvement [abstract 518] Blood. 110 159a
35. D Hoelzer 2008 Recent results in the treatment of Burkitt lymphomas Ann Oncol. 19 suppl 4 iv83
36. Abramson JS, Barnes JA, Toomey CE, et al. Rituximab added to CODOX-M/IVAC is highly effective in HIV-negative and HIV-positive Burkitt lymphoma [abstract 3595]. Blood. 2008;112.
37. VP Kenkre W Stock 2009 Burkitt lymphoma/leukemia: improving prognosis Clin Lymphoma Myeloma. 9 Suppl 3 S231 238 19778846
38. Y Nomura K Karube R Suzuki, et al. 2008 High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients Cancer Sci. 99 246 252 1:CAS:528:DC%2BD1MXjs1ygtLg%3D 10.1111/j.1349-7006.2007.00681.x 18271922 (Pubitemid 351228476)
39. A Carbone A Gloghini A Aiello A Testi A Cabras 2010 B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology Hum Pathol. 41 621 631 1:CAS:528:DC%2BC3cXkvFOjt7g%3D 10.1016/j.humpath.2009.10.027 20398809
40. C Bellan L Stefano F de Giulia EA Rogena L Lorenzo 2009 Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach Hematol Oncol. 27 182 185 10.1002/hon.914 19670467
41. Hasserjian RP, Ott G, Elenitoba-Johnson KS, Balague-Ponz O, de Jong D, de Leval L. Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop. 2009:e-published.
42. A Karsan RD Gascoyne RW Coupland JD Shepherd GL Phillips DE Horsman 1993 Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies Leuk Lymphoma. 10 433 441 1:STN:280:DyaK2c%2FgsVChtQ%3D%3D 10.3109/10428199309148200 8401180
43. A Kanungo LJ Medeiros LV Abruzzo P Lin 2006 Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis Mod Pathol. 19 25 33 1:CAS:528:DC%2BD2MXhtlSqu7zI 10.1038/modpathol. 3800500 16258503 (Pubitemid 43250976)
44. P Lin LJ Medeiros 2007 High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis Haematologica. 92 1297 1301 1:CAS:528:DC%2BD2sXht12rurrF 10.3324/haematol.11263 18024366 (Pubitemid 350144145)
45. M Snuderl OK Kolman YB Chen, et al. 2010 B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma Am J Surg Pathol. 34 327 340 10.1097/PAS.0b013e3181cd3aeb 20118770
46. D Wu BL Wood R Dorer JR Fromm 2010 "Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression Am J Clin Pathol. 134 258 265 10.1309/AJCP7YLDTJPLCE5F 20660329
47. CE Keller S Nandula J Fisher, et al. 2008 The spectrum of B-cell non-Hodgkin lymphomas with dual IgH-BCL2 and BCL6 translocations Am J Clin Pathol. 130 193 201 1:CAS:528:DC%2BD1cXhtVegtbjE 10.1309/ELPKF130Q0MCMWU8 18628087
48. GW van Imhoff EJ Boerma B van der Holt, et al. 2006 Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma J Clin Oncol. 24 4135 4142 10.1200/JCO.2006.05. 5897 16943530 (Pubitemid 46622290)